Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes

Primary Care Diabetes

Volumn 9, Issue 2, 2015, Pages 135-141

  Lin, Shi Dou ^a   Tsai, Shih Tzer ^b   Tu, Shih Te ^a   Su, Ching Chieh ^c,d   Chen, Jung Fu ^e   Lu, Chieh Hsiang ^f,g   Wang, Chao Hung ^h   Yu, Neng Chun ⁱ   Hsu, Shang Ren ^a   Hsieh, Ming Chia ^a,j,k  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CARDINAL TIEN HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^g NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^h MACKAY MEMORIAL HOSPITAL   (Taiwan)

ⁱ Yu Neng Chun Diabetes Clinic   (Taiwan)

^j CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^k CHINA MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

Glycemic target; Insulin therapy; Predictors; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; GLYCEMIC INDEX; GOAL ATTAINMENT; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TAIWAN; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924341095     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2014.05.005     Document Type: Article

References (38)

1. I.M. Stratton, A.I. Adler, and H.A. Neil Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
2. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 Suppl. 1 2013 S11 S66
3. P. Chatterji, H. Joo, and K. Lahiri Racial/ethnic- and education-related disparities in the control of risk factors for cardiovascular disease among individuals with diabetes Diabetes Care 35 2012 305 312
4. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012
5. D. Giugliano, M.I. Maiorino, and G. Bellastella Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review J. Diabetes Complications 25 2011 275 281
6. D. Giugliano, M.I. Maiorino, and G. Bellastella Treatment regimens with insulin analogues and hemoglobin A1c target of <7% in type 2 diabetes: a systematic review Diabetes Res. Clin. Pract. 92 2011 1 10
7. P.C. Tong, G.T. Ko, and W.Y. So Use of anti-diabetic drugs and glycemic control in type 2 diabetes - the Hong Kong Diabetes Registry Diabetes Res. Clin. Pract. 82 2008 346 352
8. A.J. Karter, H.H. Moffet, and J. Liu Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry Am. J. Manag. Care 11 2005 262 270
9. S. Varma, L.L. Boyle, M.R. Varma, and G.A. Piatt Controlling the ABCs of diabetes in clinical practice: a community-based endocrinology practice experience Diabetes Res. Clin. Pract. 80 2008 89 95
10. V. Owen, I. Seetho, and I. Idris Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes Diabetes Obes. Metab. 12 2010 865 870
11. G.A. Nichols, T.A. Hillier, K. Javor, and J.B. Brown Predictors of glycemic control in insulin-using adults with type 2 diabetes Diabetes Care 23 2000 273 277
12. D. Giugliano, M. Maiorino, and G. Bellastella Relationship of baseline HbA1c, HbA1c change and HbA1c target of <7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials Int. J. Clin. Pract. 65 2011 602 612
13. V. Fonseca, J. Gill, R. Zhou, and J. Leahy An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycemic control and hypoglycemia Diabetes Obes. Metab. 13 2011 814 822
14. R. Retnakaran, and D.J. Drucker Intensive insulin therapy in newly diagnosed type 2 diabetes Lancet 371 2008 1725 1726
15. A. Ceriello, M.A. Ihnat, and J.E. Thorpe Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications J. Clin. Endocrinol. Metab. 94 2009 410 415
16. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
17. D. Raccah, H. Hanaire-Broutin, and C. Sert-Langeron Insulin initiation in type 2 diabetic patients admitted in hospital in France and follow-up at 1 year Diabetes Metab. 32 2006 244 250
18. S. Jones, M. Benroubi, and C. Castell Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study Curr. Med. Res. Opin. 25 2009 691 700
19. M. Vähätalo, T. Rönnemaa, and J. Viikari Factors affecting the efficacy of starting insulin treatment in Type 2 diabetic patients. A retrospective evaluation Scand. J. Prim. Health Care 21 2003 230 236
20. R.W. Hutubessy, H. Vondeling, and J.J. Sonnaville Insulin therapy in patients with type 2 diabetes mellitus. Shared care versus secondary outpatient care in The Netherlands Dis. Manage. Health Outcomes 9 2001 337 344
21. A.J. Karter, H.H. Moffet, and J. Liu Glycemic response to newly initiated diabetes therapies Am. J. Manag. Care 13 2007 598 606
22. M. Korytkowski When oral agents fail: practical barriers to starting insulin Int. J. Obes. Relat. Metab. Disord. 26 Suppl. 3 2002 S18 S24
23. L.M. Hunt, M.A. Valenzuela, and J.A. Pugh NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance Diabetes Care 20 1997 292 298
24. J.B. Buse, B.H. Wolffenbuttel, and W.H. Herman The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: comparing the durability of lispro mix 75/25 and glargine Diabetes Care 34 2011 249 255
25. P.H. Kann, T. Wascher, and V. Zackova Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride Exp. Clin. Endocrinol. Diabetes 114 2006 527 532
26. M.C. Riddle, J. Rosenstock, and J. Gerich The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 2003 3080 3086
27. H. Yki-Järvinen, L. Juurinen, and M. Alvarsson Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups Diabetes Care 30 2007 1364 1369
28. R.G. Bretzel, U. Nuber, and W. Landgraf Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycemic agents (APOLLO): an open randomised controlled trial Lancet 371 2008 1073 1084
29. H.U. Janka, G. Plewe, and M.C. Riddle Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 28 2005 254 259
30. H.U. Janka, G. Plewe, and K. Busch Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus J. Am. Geriatr. Soc. 55 2007 182 188
31. J.C. Chan, J.J. Gagliardino, and S.H. Baik Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS) Diabetes Care 32 2009 227 233
32. B.A. Briesacher, S.E. Andrade, H. Fouayzi, and K.A. Chan Comparison of drug adherence rates among patients with seven different medical conditions Pharmacotherapy 28 2008 437 443
33. J.B. Buse, B.H. Wolffenbuttel, and W.H. Herman The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine Diabetes Care 34 2011 249 255
34. J.K. Malone, S. Bai, and B.N. Campaigne Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycemic control in patients with Type 2 diabetes Diabet. Med. 22 2005 374 381
35. U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of Type II diabetes: a progressive disease Diabetes 44 1995 1249 1258
36. T.Y. Wu, A. Majeed, and K.N. Kuo An overview of the healthcare system in Taiwan Lond. J. Prim. Care 3 2010 115 119
37. M. Halbron, S. Jacqueminet, and C. Sachon Insulin therapy for type 2 diabetes: premixed or basal-prandial Diabetes Metab. 33 2007 313 316
38. J.S. Wang, S.T. Tu, and I.T. Lee Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring Diabetes Metab. Res. Rev. 27 2011 79 84